Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 COVID-19 Outpatients: A Monocentric Retrospective Cohort Study
et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2203116 (date from earlier preprint)
, Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 COVID-19 Outpatients: A Monocentric.., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2203116 (date from earlier preprint)
Retrospective 10,429 outpatients in France, 8,315 treated with HCQ+AZ a median of 4 days from symptom onset, showing significantly lower mortality with treatment.
|
risk of death, 83.0% lower, HR 0.17, p < 0.001, treatment 5 of 8,315 (0.1%), control 11 of 2,114 (0.5%), NNT 217, adjusted per study.
|
|
risk of ICU admission, 44.0% lower, HR 0.56, p = 0.18, treatment 17 of 8,315 (0.2%), control 7 of 2,114 (0.3%), NNT 789, adjusted per study.
|
|
risk of hospitalization, 4.0% lower, HR 0.96, p = 0.77, treatment 214 of 8,315 (2.6%), control 64 of 2,114 (3.0%), adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Million et al., 27 May 2021, retrospective, France, peer-reviewed, 28 authors, average treatment delay 4.0 days, dosage 200mg tid days 1-10, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
Abstract: Medicine
Original Research
Early combination therapy with hydroxychloroquine and
azithromycin reduces mortality in 10,429 COVID-19
outpatients
Matthieu MILLION1, *, Jean-Christophe LAGIER1 , Hervé TISSOT-DUPONT1 , Isabelle RAVAUX1 , Catherine DHIVER1 ,
Christelle TOMEI1 , Nadim CASSIR1 , Léa DELORME2 , Sébastien CORTAREDONA2 , Sophie AMRANE2 , Camille AUBRY2 ,
Karim BENDAMARDJI1 , Cyril BERENGER2 , Barbara DOUDIER1 , Sophie EDOUARD1 , Marie HOCQUART2 , Morgane MAILHE1 ,
Coralie PORCHETO1 , Piseth SENG1 , Catherine TRIQUET1 , Stéphanie GENTILE3 , Elisabeth JOUVE3 ,
Audrey GIRAUD-GATINEAU2 , Herve CHAUDET2 , Laurence CAMOIN-JAU4 , Philippe COLSON1 , Philippe GAUTRET2 ,
Pierre-Edouard FOURNIER2 , Baptiste MAILLE5 , Jean-Claude DEHARO5 , Paul HABERT6 , Jean-Yves GAUBERT6 ,
Alexis JACQUIER6 , Stéphane HONORE7 , Katell GUILLON-LORVELLEC1 , Yolande OBADIA2 ,
Philippe PAROLA2 , Philippe BROUQUI1 , Didier RAOULT1
1
IHU-Méditerranée Infection, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille (AP-HM), Institut de recherche pour le développement (IRD),
Reviews
in
Cardiovascular
Unité Microbes Evolution Phylogénie et Infections (MEPHI),13005 Marseille, France
2
IHU-Méditerranée Infection, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille (AP-HM), Institut de recherche pour le développement (IRD),
Unité Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), Service de santé des armées (SSA), 13005 Marseille, France
3
EA 3279: CEReSS - Health Service Research and Quality of Life Center, Service d'Evaluation Médicale, Aix Marseille Univ, Assistance Publique Hôpitaux de
Marseille, 13005 Marseille, France
4
Laboratoire D'Hématologie, Hôpital de La Timone, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France
5
Service de Cardiologie, Centre Hospitalier Universitaire La Timone, Assistance Publique Hôpitaux de Marseille, Aix Marseille Univ, C2VN, 13005 Marseille,
France
6
Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, Aix Marseille Univ, LIIE, CERIMED, 13005 Marseille, France
7
Service de Pharmacie, Hôpital Timone, Laboratoire de Pharmacie Clinique, Aix Marseille Université AP-HM, 13005 Marseille, France
*Correspondence: matthieu.million@gmail.com (Matthieu MILLION)
DOI:10.31083/j.rcm2203116
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Submitted: 10 August 2021 Revised: 27 August 2021 Accepted: 30 August 2021 Published: 24 September 2021
We evaluated the age-specific mortality of unselected adult outpatients infected with SARS-CoV-2 treated early in a dedicated COVID19 day hospital and we assessed whether the use of hydroxychloroquine (HCQ) + azithromycin (AZ) was associated with improved survival in this cohort. A retrospective monocentric cohort study was
conducted in the day hospital of our center from March to December 2020 in adults with PCR-proven infection who were treated as
outpatients with a standardized protocol. The primary endpoint was
6-week mortality, and secondary endpoints were transfer to the intensive care unit and hospitalization rate. Among 10,429 patients
(median age, 45 [IQR 32–57] years; 5597 [53.7%] women), 16 died
(0.15%). The infection fatality rate was 0.06% among the 8315 patients treated with HCQ+AZ. No deaths occurred among the 8414 patients younger than 60 years. Older age and male sex were associated
with a higher risk of death, ICU transfer, and..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.